<DOC>
	<DOC>NCT02230904</DOC>
	<brief_summary>The primary objective of the study is to compare the adhesiveness of 2 different patch formulations of Rotigotine using the largest patch size of 40 cm^2, under the assumption that both patch formulations show similar adhesiveness properties.</brief_summary>
	<brief_title>A Study to Compare the Adhesiveness of 2 Different Rotigotine Patches Used for the Treatment of Parkinson's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>Subject has a diagnosis of idiopathic Parkinson's Disease Subject has been on continuous treatment with commercially available Rotigotine transdermal patches (NeuproÂ®) for at least 3 months prior to enrollment Subject has been taking a stable Rotigotine dose including an 8 mg/24 hours (40 cm^2) patch for at least 2 weeks prior to enrollment Subject has any medical or psychiatric condition which, in the opinion of the investigator, could jeopardize or would compromise the subject's wellbeing or ability to participate in this study Subject has a history of significant skin hypersensitivity to adhesives or other transdermal products or recently unsolved contact dermatitis Subject has a history or present condition of an atopic or eczematous Dermatitis, Psoriasis, or an active skin disease Subject has a lifetime history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response ('yes') to either Question 4 or Question 5 of the ColumbiaSuicide Severity Rating Scale (CSSRS) at Screening (Visit 1) or Baseline (Visit 2)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Rotigotine patch</keyword>
	<keyword>Neupro</keyword>
	<keyword>Parkinson's Disease</keyword>
</DOC>